KR101080577B1 - 활성성분의 결장 표적화 전달을 위한 제제 - Google Patents
활성성분의 결장 표적화 전달을 위한 제제 Download PDFInfo
- Publication number
- KR101080577B1 KR101080577B1 KR1020057002387A KR20057002387A KR101080577B1 KR 101080577 B1 KR101080577 B1 KR 101080577B1 KR 1020057002387 A KR1020057002387 A KR 1020057002387A KR 20057002387 A KR20057002387 A KR 20057002387A KR 101080577 B1 KR101080577 B1 KR 101080577B1
- Authority
- KR
- South Korea
- Prior art keywords
- pectin
- beads
- solution
- colon
- release
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
샘플 | 억제 직경(mm) | |||
T0 | T30 | T60 | T120 | |
초음파후의 상등액 |
31 | 25 | 18 | - |
21 | - | 18 | 14 | |
초음파후의 캡(Cap) |
30 | 28 | 24 | - |
22.5 | - | 19.5 | 19 |
샘플 | 평가된 활성(U/mL) |
부피(mL) | 총 평가 활성 (U) |
초음파후의 상등액 |
2.0 | 92 | 184 |
초음파후의 캡 |
1.5 | 10 | 15 |
샘플 | 평균억제직경(mm) |
펙틴/용액A (용액B)-T0 |
23 |
펙틴/용액 A-T3h | 19 |
분해된 비드 - T0 | 24 |
분해된 비드 - T3h | 18 |
샘플 | 평가된 활성 |
펙틴(용액 B) | 2.4 |
분해된 비드 | 2.4 |
Claims (15)
- i)β-락타마아제 및 ii) 에리트로마이신 에스터라아제(erythromycin esterase)를 포함하는 군으로부터 선택되는 활성작용제의 경구투여 및 결장방출(colonic release)을 위한 다중입자형 제제(multiparticular dosage form).
- 삭제
- 제1항에 있어서, 상기 활성작용제를 둘러싸는 양이온성 염 형태의 펙틴 비드(beads of pectin)을 포함하고, 상기 펙틴은 양이온성 폴리머에 의해 망상화된(reticulated) 다중입자형 제제.
- 제3항에 있어서, 상기 양이온성 폴리머는 폴리에틸렌이민(polyethylenimine), 폴리라이신(polylysine), 키토산 및 이들의 유도체를 포함하는 군으로부터 선택되는 다중입자형 제제.
- 제3항에 있어서, 상기 양이온성 폴리머는 10,000 - 100,000 달톤의 분자량을 갖는 다중입자형 제제.
- 제5항에 있어서, 상기 양이온성 폴리머는 20,000 - 50,000 달톤의 분자량을 갖는 다중입자형 제제.
- 제3항에 있어서, 상기 펙틴염은 아미드화(amidated) 또는 비 아미드화(non amidated) 펙틴으로부터 제조된 칼슘 펙티네이트인 다중입자형 제제.
- 제4항 내지 제7항 중 어느 한 항에 기재된 경구투여 및 결장전달용 다중입자형 제제를 제조하기 위한 방법으로서,a) i)β-락타마아제 및 ii) 에리트로마이신 에스터라아제(erythromycin esterase)를 포함하는 군에서 선택되는 활성 작용제를 포함하는 펙틴용액을 제조하는 단계;b) 상기 펙틴용액을 염화칼슘용액에 첨가하여 양이온적으로 가교된 펙틴 비드를 형성하는 단계; 및c) 폴리에틸렌이민 용액으로 상기 펙틴 비드를 망상화시키는 단계를 포함하는, 방법.
- 제8항에 있어서,a) 4 - 10%(m/v)의 펙틴용액을 제조하는 단계;b) 상기 펙틴용액을 2 - 10%(m/v)의 염화칼슘용액에 첨가하여 양이온적으로 가교된 펙틴 비드를 형성하는 단계; 및c) 0.5 - 2%(m/v)의 폴리에틸렌이민 용액으로 상기 펙틴 비드를 망상화시키는 단계를 포함하는, 방법.
- 제8항에 있어서,상기 펙틴 용액은 4 - 7%(m/v) 용액인, 방법
- 제9항에 있어서,상기 펙틴용액은 6%의 펙틴용액이고, 상기 염화칼슘용액은 6%의 염화칼슘용액이고, 상기 폴리에틸렌이민 용액은 1% 또는 0.6%의 폴리에틸렌이민 용액인,방법.
- 제8항에 기재된 방법에 의해 얻어지는, 활성 작용제의 경구투여 및 결장방출을 위한 다중입자형 제제.
- 제9항에 기재된 방법에 의해 얻어지는, 활성 작용제의 경구투여 및 결장방출을 위한 다중입자형 제제.
- 제10항에 기재된 방법에 의해 얻어지는, 활성 작용제의 경구투여 및 결장방출을 위한 다중입자형 제제.
- 제11항에 기재된 방법에 의해 얻어지는, 활성 작용제의 경구투여 및 결장방출을 위한 다중입자형 제제.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0210151A FR2843301B1 (fr) | 2002-08-09 | 2002-08-09 | Forme galenique pour la delivrance colique de principes actifs |
FR02/10151 | 2002-08-09 | ||
FR02/13514 | 2002-10-29 | ||
FR0213514A FR2843302B1 (fr) | 2002-08-09 | 2002-10-29 | Forme galenique pour la delivrance colique de principes actifs |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050083628A KR20050083628A (ko) | 2005-08-26 |
KR101080577B1 true KR101080577B1 (ko) | 2011-11-04 |
Family
ID=30772009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057002387A KR101080577B1 (ko) | 2002-08-09 | 2003-08-06 | 활성성분의 결장 표적화 전달을 위한 제제 |
Country Status (14)
Country | Link |
---|---|
US (2) | US7485294B2 (ko) |
EP (2) | EP1992336A3 (ko) |
JP (1) | JP2006500359A (ko) |
KR (1) | KR101080577B1 (ko) |
CN (1) | CN1681480B (ko) |
AT (1) | ATE432066T1 (ko) |
AU (1) | AU2003274229B2 (ko) |
BR (1) | BR0313469A (ko) |
CA (1) | CA2495291A1 (ko) |
DE (1) | DE60327772D1 (ko) |
ES (1) | ES2327630T3 (ko) |
FR (1) | FR2843302B1 (ko) |
MX (1) | MXPA05001607A (ko) |
WO (1) | WO2004016248A2 (ko) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4694145B2 (ja) * | 2004-05-17 | 2011-06-08 | 株式会社 メドレックス | 経口腸溶性製剤 |
JP2008529996A (ja) * | 2005-02-09 | 2008-08-07 | ダ・ボルテラ | 活性因子の大腸送達 |
CN101257892B (zh) * | 2005-05-18 | 2013-01-02 | 达沃尔泰拉公司 | 吸附剂的结肠递送 |
WO2006129386A1 (ja) * | 2005-06-03 | 2006-12-07 | Medrx Co., Ltd. | 経口腸溶性医薬組成物 |
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
FI119190B (fi) * | 2006-06-21 | 2008-08-29 | Ipsat Therapies Oy | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
US20080124279A1 (en) * | 2006-11-17 | 2008-05-29 | Antoine Andremont | Colonic delivery using Zn/pectin beads with a Eudragit coating |
US8273376B2 (en) * | 2006-11-17 | 2012-09-25 | Da Volterra | Colonic delivery of metallo-dependent enzymes |
FI119678B (fi) * | 2006-11-28 | 2009-02-13 | Ipsat Therapies Oy | Beta-laktamaasin käyttö |
GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
GB0714226D0 (en) * | 2007-07-20 | 2007-08-29 | Therapeutics Ltd E | anti-bacterial combination therapy |
WO2009037264A2 (en) * | 2007-09-17 | 2009-03-26 | Da Volterra | Colonic delivery of antimicrobial agents |
GB0719771D0 (en) * | 2007-10-10 | 2007-11-21 | Therapeutics Ltd E | Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma |
GB0813211D0 (en) | 2008-07-18 | 2008-08-27 | E Therapeutics Plc | Antibacterial combination therapy for the treatment of gram positive bacterial infections |
FR2950252B1 (fr) * | 2009-09-23 | 2012-01-20 | Centre Nat Rech Scient | Forme galenique capable d'adsorber de maniere specifique les molecules indesirables |
BR112012021275B1 (pt) | 2010-02-23 | 2021-07-27 | Da Volterra | Formulação compreendendo um adsorvente misturado com carragenina, para entrega oral e liberação controlada de adsorventes no intestino, e, uso de uma formulação |
FI20105572A0 (fi) | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
EP3132033B1 (en) | 2014-04-17 | 2019-10-30 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
JP6803328B2 (ja) | 2014-08-28 | 2021-01-06 | シンセティック バイオロジクス,インコーポレイテッド | 大腸菌ベースでのベータラクタマーゼ生産 |
JP6672277B2 (ja) | 2014-10-08 | 2020-04-01 | シンセティック・バイオロジクス・インコーポレイテッド | ベータラクタマーゼ製剤およびその使用 |
FR3027307B1 (fr) | 2014-10-16 | 2016-11-04 | Azurrx Sas | Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant |
US9744221B2 (en) | 2014-12-23 | 2017-08-29 | Synthetic Biologics, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
CA2977385C (en) | 2015-02-23 | 2024-04-09 | Synthetic Biologics, Inc. | Carbapenemases for use with antibiotics for the protection of the intestinal microbiome |
EP3265119B1 (en) | 2015-03-06 | 2023-10-11 | Theriva Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
US10182993B2 (en) | 2015-04-06 | 2019-01-22 | Patheon Softgels Inc. | Compositions for colonic delivery of drugs |
ES2922009T3 (es) | 2016-02-23 | 2022-09-06 | Da Volterra | Variantes de beta-lactamasa |
US10988749B2 (en) | 2016-02-23 | 2021-04-27 | Da Volterra | Beta-lactamase variants |
CN111511350B (zh) | 2017-07-07 | 2023-10-13 | 埃皮辛特瑞柯斯公司 | 用于治疗剂的肠胃外施用的组合物 |
EP3701022B1 (en) | 2017-10-25 | 2023-03-01 | Da Volterra | Beta-lactamase variants |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959457A (en) * | 1970-06-05 | 1976-05-25 | Temple University | Microparticulate material and method of making such material |
US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
SE459005B (sv) * | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
FR2608456B1 (fr) * | 1986-12-18 | 1993-06-18 | Mero Rousselot Satia | Microcapsules a base de gelatine et de polysaccharides et leur procede d'obtention |
FR2613624B1 (fr) * | 1987-04-10 | 1990-11-23 | Roussy Inst Gustave | Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines |
US4963368A (en) * | 1988-04-18 | 1990-10-16 | Nabisco Brands, Inc. | Oxidoreductase enzyme stabilized highly unsaturated fatty acids and derivatives of such acids |
RU2104084C1 (ru) | 1989-02-16 | 1998-02-10 | Бритиш Технолоджи Груп Лимитед | Капсула дозируемого выброса |
DK0454044T3 (da) * | 1990-04-25 | 1996-04-22 | Hoechst Ag | Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof |
JPH0413741A (ja) * | 1990-05-02 | 1992-01-17 | Chisso Corp | ペクチン・ポリリシン高分子電解質複合体 |
JPH0413724A (ja) | 1990-05-02 | 1992-01-17 | Chisso Corp | 可溶性ポリイミド、その製造法及び液晶配向膜用塗布液 |
SE9002339L (sv) * | 1990-07-04 | 1992-01-05 | Kabi Pharmacia Ab | Terapeutisk komposition och foerfarande foer dess framstaellning |
KR930006431B1 (ko) * | 1990-10-11 | 1993-07-16 | 재단법인 한국화학연구소 | 약물의 미세캡슐화 방법 |
FI920206A0 (fi) * | 1992-01-17 | 1992-01-17 | Pekka Untamo Heino | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
DE59303759C5 (de) * | 1992-01-17 | 2009-04-09 | Alfatec-Pharma Gmbh | Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung |
US5718969A (en) * | 1993-08-25 | 1998-02-17 | Fmc Corporation | Nonaggregating hydrocolloid microparticulates, intermediates therefor, and processes for their preparation |
WO1997027843A2 (en) * | 1996-01-30 | 1997-08-07 | Advanced Polymer Systems, Inc. | Targeted delivery of drugs to the lower gastrointestinal tract |
PL332669A1 (en) * | 1996-10-09 | 1999-09-27 | Givaudan Roure Int | Method of obtaining minute beads constituting a food additive |
US6531152B1 (en) * | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
IL130303A0 (en) * | 1999-06-03 | 2000-06-01 | M G Novobiotech Ltd | A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use |
US6632451B2 (en) * | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
IL152127A0 (en) * | 2002-10-06 | 2003-05-29 | Bio Balance Corp | Probiotic compositions for the treatment of inflammatory bowel disease |
-
2002
- 2002-10-29 FR FR0213514A patent/FR2843302B1/fr not_active Expired - Lifetime
-
2003
- 2003-08-06 CA CA002495291A patent/CA2495291A1/fr not_active Abandoned
- 2003-08-06 EP EP20080163660 patent/EP1992336A3/fr not_active Withdrawn
- 2003-08-06 AU AU2003274229A patent/AU2003274229B2/en not_active Ceased
- 2003-08-06 MX MXPA05001607A patent/MXPA05001607A/es active IP Right Grant
- 2003-08-06 BR BR0313469-5A patent/BR0313469A/pt not_active Application Discontinuation
- 2003-08-06 US US10/524,318 patent/US7485294B2/en not_active Expired - Fee Related
- 2003-08-06 ES ES03758212T patent/ES2327630T3/es not_active Expired - Lifetime
- 2003-08-06 DE DE60327772T patent/DE60327772D1/de not_active Expired - Lifetime
- 2003-08-06 EP EP03758212A patent/EP1526841B1/fr not_active Expired - Lifetime
- 2003-08-06 JP JP2004528586A patent/JP2006500359A/ja active Pending
- 2003-08-06 AT AT03758212T patent/ATE432066T1/de not_active IP Right Cessation
- 2003-08-06 CN CN038213656A patent/CN1681480B/zh not_active Expired - Fee Related
- 2003-08-06 WO PCT/FR2003/002474 patent/WO2004016248A2/fr active Application Filing
- 2003-08-06 KR KR1020057002387A patent/KR101080577B1/ko active IP Right Grant
-
2008
- 2008-12-29 US US12/345,647 patent/US7833765B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ATE432066T1 (de) | 2009-06-15 |
FR2843302B1 (fr) | 2004-10-22 |
CA2495291A1 (fr) | 2004-02-26 |
WO2004016248A3 (fr) | 2004-04-08 |
MXPA05001607A (es) | 2005-09-20 |
EP1992336A3 (fr) | 2009-05-13 |
JP2006500359A (ja) | 2006-01-05 |
CN1681480A (zh) | 2005-10-12 |
US20050249716A1 (en) | 2005-11-10 |
US20090162339A1 (en) | 2009-06-25 |
FR2843302A1 (fr) | 2004-02-13 |
WO2004016248A2 (fr) | 2004-02-26 |
CN1681480B (zh) | 2010-04-14 |
EP1526841A2 (fr) | 2005-05-04 |
US7833765B2 (en) | 2010-11-16 |
AU2003274229B2 (en) | 2009-05-21 |
US7485294B2 (en) | 2009-02-03 |
KR20050083628A (ko) | 2005-08-26 |
ES2327630T3 (es) | 2009-11-02 |
BR0313469A (pt) | 2005-07-12 |
EP1992336A2 (fr) | 2008-11-19 |
DE60327772D1 (de) | 2009-07-09 |
AU2003274229A1 (en) | 2004-03-03 |
EP1526841B1 (fr) | 2009-05-27 |
WO2004016248A8 (fr) | 2004-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101080577B1 (ko) | 활성성분의 결장 표적화 전달을 위한 제제 | |
Maroni et al. | Film coatings for oral colon delivery | |
Anal et al. | Chitosan–alginate multilayer beads for controlled release of ampicillin | |
Oliveira et al. | Chitosan–pectin multiparticulate systems associated with enteric polymers for colonic drug delivery | |
CN101257892B (zh) | 吸附剂的结肠递送 | |
Das | Pectin based multi-particulate carriers for colon-specific delivery of therapeutic agents | |
JP2002521346A (ja) | 多糖類を利用した大腸選択性薬物伝達組成物および医薬製剤 | |
CA2678131A1 (en) | Colonic delivery using zn/pectin beads with a eudragit coating. | |
CA2868592C (en) | Capsule which disintegrates specifically in large intestine | |
CA2595526A1 (en) | Colonic delivery of active agents | |
Bourgeois et al. | Polymer colon drug delivery systems and their application to peptides, proteins, and nucleic acids | |
Ibrahim | Advances in polysaccharide-based oral colon-targeted delivery systems: The journey so far and the road ahead | |
Essa et al. | Smart liquids for oral controlled drug release: An overview of alginate and non-alginate based systems | |
US8273376B2 (en) | Colonic delivery of metallo-dependent enzymes | |
Muvva et al. | Modified pectins for colon-specific drug delivery | |
US20240082168A1 (en) | Controlled drug release formulation | |
JP5715139B2 (ja) | 消化管に存在する望ましくない分子を特異的に吸着し得る医学製剤 | |
FR2843301A1 (fr) | Forme galenique pour la delivrance colique de principes actifs | |
Vibhooti et al. | Eudragit and chitosan—The two most promising polymers for colon drug delivery | |
Fish et al. | Drug delivery to the colon | |
Hirsch et al. | Novel polymeric excipients for colon‐targeting | |
Goracinova et al. | Drug targeting in IBD treatment–Existing and new approaches | |
BAUTZOVÁ | THESE en Co-tutelle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141014 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151021 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161018 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20171011 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180920 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190925 Year of fee payment: 9 |